EA202090240A1 - Усовершенствованная молекула полипептида с двойной специфичностью - Google Patents
Усовершенствованная молекула полипептида с двойной специфичностьюInfo
- Publication number
- EA202090240A1 EA202090240A1 EA202090240A EA202090240A EA202090240A1 EA 202090240 A1 EA202090240 A1 EA 202090240A1 EA 202090240 A EA202090240 A EA 202090240A EA 202090240 A EA202090240 A EA 202090240A EA 202090240 A1 EA202090240 A1 EA 202090240A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- polypeptide molecule
- improved double
- double specificity
- specificity polypeptide
- binding site
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 2
- 230000027455 binding Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 239000012642 immune effector Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Настоящее изобретение относится к биспецифической молекуле полипептида, включающей первую полипептидную цепь и вторую полипептидную цепь, обеспечивающие связывающий участок, полученный из Т-клеточного рецептора (ТКР), специфичного к вирусному пептидному эпитопу, ассоциированному с главным комплексом гистосовместимости (МНС), и связывающий участок, полученный из антитела, способного к привлечению иммунных эффекторных клеток человека за счет специфического связывания с поверхностным антигеном указанных клеток, а также к способам получения биспецифической молекулы полипептида и их применению.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862658318P | 2018-04-16 | 2018-04-16 | |
PCT/EP2018/069157 WO2019012141A1 (en) | 2017-07-14 | 2018-07-13 | IMPROVED POLYPEPTIDE MOLECULE WITH DOUBLE SPECIFICITY |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202090240A1 true EA202090240A1 (ru) | 2020-05-08 |
Family
ID=70847669
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090240A EA202090240A1 (ru) | 2018-04-16 | 2018-07-13 | Усовершенствованная молекула полипептида с двойной специфичностью |
EA202090250A EA202090250A1 (ru) | 2018-04-16 | 2018-07-13 | Усовершенствованная молекула полипептида с двойной специфичностью |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090250A EA202090250A1 (ru) | 2018-04-16 | 2018-07-13 | Усовершенствованная молекула полипептида с двойной специфичностью |
Country Status (1)
Country | Link |
---|---|
EA (2) | EA202090240A1 (ru) |
-
2018
- 2018-07-13 EA EA202090240A patent/EA202090240A1/ru unknown
- 2018-07-13 EA EA202090250A patent/EA202090250A1/ru unknown
Also Published As
Publication number | Publication date |
---|---|
EA202090250A1 (ru) | 2020-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20200014A (es) | Molécula de polipéptido con especificidad dual mejorada | |
DOP2019000059A (es) | Anticuerpos de unión a cd3 | |
CL2021001986A1 (es) | Anticuerpos y receptores quiméricos de antígenos específicos para receptor 1 huérfano tipo receptor tirosina-cinasa (ror1). | |
EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
PE20181451A1 (es) | Anticuerpos neutralizadores del virus de inmunodeficiencia humana | |
EA201992469A1 (ru) | Антигенспецифические иммунные эффекторные клетки | |
RU2016151235A (ru) | Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус | |
EA201500741A1 (ru) | ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ | |
AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
PE20210517A1 (es) | Anticuerpos anti-hla-g y utilizacion de los mismos | |
CO2022006909A2 (es) | Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso | |
AU2015287227A8 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
EA202190573A1 (ru) | Композиции и способы перепрограммирования tcr с применением гибридных белков | |
NI201800113A (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
CL2020001726A1 (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
CY1120212T1 (el) | Πεπτιδια | |
AR112228A1 (es) | Molécula de polipéptido con especificidad dual mejorada | |
EA201792661A1 (ru) | Способ получения антител против т-клеточного рецептора | |
AR117735A1 (es) | ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USO | |
RU2017124512A (ru) | Способ определения антител, вызывающих комплемент-зависимую цитотоксичность | |
MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. | |
EA202090240A1 (ru) | Усовершенствованная молекула полипептида с двойной специфичностью | |
EA202190424A1 (ru) | Способ оценки функционального состояния химерного антигенного рецептора (car) | |
PH12020500095A1 (en) | Improved dual specific polypeptide molecule | |
MX2022003191A (es) | Terapias de combinacion con anticuerpos entpd2 y cd73. |